RNA Molecules Offer New Clues for Heart Disease Diagnosis and Treatment
en-GBde-DEes-ESfr-FR

RNA Molecules Offer New Clues for Heart Disease Diagnosis and Treatment

17/11/2026 Compuscript Ltd


A review published in Genes & Diseases highlights how RNA molecules could open new avenues for diagnosing and treating heart disease. Researchers from Shandong Second Medical University and Qingdao University examine four groups of non-coding RNAs that influence abnormal heart muscle growth, damage caused by reduced blood supply, and heart failure.
Unlike RNAs that provide instructions for making proteins, non-coding RNAs help regulate cellular activity. The review focuses on small nucleolar RNAs, PIWI-interacting RNAs, tRNA-derived small RNAs, and circular RNAs. These molecules are attracting attention as potential biomarkers and therapeutic targets beyond the better-studied microRNAs and long non-coding RNAs.
The article brings together evidence that these RNA groups can affect gene activity, protein function, cell survival, and cardiac fibrosis, the formation of scar tissue in the heart. Their effects vary: some molecules promote damage, while others appear to protect heart cells or limit harmful structural changes.
Circular RNAs receive attention because their downstream mechanisms are comparatively well characterised. They can interact with proteins or influence networks involving microRNAs and messenger RNAs, altering pathways linked to cardiac growth, inflammation, and cell death. Research into the other three RNA groups is developing, although many functional mechanisms remain uncertain.
The review describes experimental findings that illustrate therapeutic possibilities. In mice, inhibiting a PIWI-interacting RNA called CHAPIR reduced pathological heart muscle enlargement, lessened fibrosis, and improved cardiac performance. Targeting another molecule, CFRPi, also reduced fibrosis and improved heart function in a mouse model of pressure overload.
Potential diagnostic applications are emerging alongside these treatment strategies. Studies have identified altered RNA levels in blood samples from people with heart attacks, hypertrophic cardiomyopathy, and heart failure. Such patterns could help identify disease or assess progression. Some findings suggest combining RNA measurements with established cardiac markers could improve diagnostic performance.
However, these opportunities remain under investigation. Animal results do not establish that RNA-targeted treatments will work safely in patients, and candidate biomarkers require further clinical validation. Researchers must also determine whether altered RNA levels cause disease, contribute to its progression, or simply reflect existing damage.
Developing therapies will require delivery to the heart, control of unintended effects, and assessment of toxicity and long-term safety. Understanding interactions between RNA groups will also be important.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Jingyi Wang, Jingyi Xie, Hao Chen, Wenxu Wang, Qing Liu, Xuanzhen Guo, Kun Wang, Jie Ju, The emerging roles of small nucleolar RNAs, piwi-interacting RNAs, tRNA-derived small RNAs, and circular RNAs in the regulation of cardiac hypertrophy, ischemic heart disease, and heart failure, Genes & Diseases, Volume 13, Issue 6, 2026, 101996, https://doi.org/10.1016/j.gendis.2025.101996

Funding
National Natural Science Foundation (China) 82500356
Shandong Provincial Natural Science Foundation ZR2025QC863
PhD research startup foundation of Shandong Second Medical University (China) 0215500104
Weifang science and technology development plan project for medicine (China) 2025YX039
Weifang science and technology development plan project for medicine (China) 2024YX036
Shandong Second Medical University innovation and entrepreneurship training program (China) X2024281
Jingyi Wang, Jingyi Xie, Hao Chen, Wenxu Wang, Qing Liu, Xuanzhen Guo, Kun Wang, Jie Ju, The emerging roles of small nucleolar RNAs, piwi-interacting RNAs, tRNA-derived small RNAs, and circular RNAs in the regulation of cardiac hypertrophy, ischemic heart disease, and heart failure, Genes & Diseases, Volume 13, Issue 6, 2026, 101996, https://doi.org/10.1016/j.gendis.2025.101996
Attached files
  • Image Caption: Structural characteristics and binding core proteins of C/D Box and H/ACA Box snoRNAs.
  • Image Caption: Biosynthesis pathway of piRNA and its mechanism in heart disease.
  • Image Caption: Classification of tsRNAs. tsRNAs, which include tiRNAs and tRFs, are processed from precursor or mature tRNAs.
17/11/2026 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement